News about "Akeso "

Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China

Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.

Akeso | 24/08/2026 | By News Bureau

Ivonescimab Plus Chemotherapy Approved in China for First-Line Squamous NSCLC

Ivonescimab plus chemotherapy has been approved in China for first-line squamous NSCLC, based on the HARMONi-6 Phase 3 trial and significant overall survival benefit.

Akeso | 13/08/2026 | By News Bureau |  165

Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer

Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.

Akeso | 10/08/2026 | By News Bureau

Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer

Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.

Akeso | 30/07/2026 | By News Bureau |  127

Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma

Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.

Akeso | 05/03/2026 | By Akanki |  174

China's NMPA Accepts Akeso's Gumukimab sNDa for Ankylosing Spondylitis

China’s NMPA gives approval to Akeso’s gumokimab for the treatment of active ankylosing spondylitis, supported by Phase III data showing significant symptom relief and functional improvement.

Akeso | 20/01/2026 | By News Bureau |  365

China Updates Ivonescimab Label After NSCLC Survival Gains

China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />

Akeso | 07/01/2026 | By News Bureau |  541

US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer

The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.

Akeso | 12/12/2025 | By Akanki |  427

Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer

COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.

Akeso | 15/09/2025 | By Dineshwori |  295

Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer

With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.

Akeso | 17/03/2025 | By Aishwarya |  534